医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hoya Reports Second Quarter Results;Achieves Highest Half-Year Profit

2015年10月29日 PM07:49
このエントリーをはてなブックマークに追加


 

TOKYO

Hoya Corporation (TOKYO: 7741) today announced financial results for the second quarter ended September 30, 2015.

During the quarter, the Group revenues totaled 130,165 million yen, increasing by 7.4% from the same period last year. Pre-tax profit for the quarter was 33,858 million yen, while profit for the quarter was 27,140 million yen; decrease of 1.2% and 0.7%, respectively from last year when foreign exchange gain was reported due to the decline in the value of yen against U.S. dollar.

In the Information Technology segment, demand of semiconductor and LCD panel-related products for smartphones and other telecommunications devices was favorable and drove sales expansion. On the other hand, sales in volume terms of glass disks for HDDs were below their levels of the same quarter last year. Among imaging related products, in view of the shrinkage of the market for digital cameras, sales overall held firm due to commercialization of products for other applications.

In the Life Care segment, sales in the eyeglass lens business expanded in overseas markets. The contact lens retail business reported a major increase compared to the same quarter last year when sales significantly declined following the increase in Japan’s consumption tax. Sales of medical endoscopes weakened, however, thanks to the ongoing recovery sales in the intraocular lens business for cataract surgery, overall sales in the medical related products business were strong. In addition, along with the positive impact of the depreciation of the yen, segment sales rose year on year.

For the six months ended September 30, 2015, revenues totaled 256,403 million yen, increasing by 9.4% year-on-year. Pre-tax profit posted 64,759 million yen and profit for the term was 50,790 million yen, both the best first-half profit total in the company’s history.

“Today we announced a new share repurchase program with a maximum of 14 million shares and 60 billion yen. Our policy to allocate resources in M&A opportunities and to use excess cash to reward shareholders continues,” said Hiroshi Suzuki, chief executive officer of HOYA. “Overall the Life Care segment showed healthy growth, including intraocular lens, contact lens retail as well as eyeglass lens businesses.”

HOYA also announced the interim dividends of 30 yen per share of common stock.

 

Summary of Consolidated Financial Statement

(Millions of Yen: Rounded to the nearest million)
      Three months ended   Variance   Six months ended   Variance
      Sept./14   Sept./15 (%) Sept./14   Sept./15 (%)
Revenue 121,242 130,165 7.4 234,314 256,403 9.4
Profit before tax 34,256 33,858 -1.2 56,700 64,759 14.2
Profit for the term 27,323 27,140 -0.7 45,285 50,790 12.2
Profit attributable to owners of the company 27,150 27,037 -0.4 44,948 50,381 12.1
Basic earnings per share(yen)   64.12   65.15    

105.30

  120.40  

*Results are preliminary and unaudited.

 

The full reports are available at: www.hoya.com

About HOYA

Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company and the leading supplier of innovative high-tech and medical products. Hoya is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, Hoya currently employs a multinational workforce of over 34,000 people. For more information, please visit http://www.hoya.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151029005678/en/

CONTACT

Hoya Group
Akiko Chiba, +81-3-3952-6416
Public Relation
HOYA-pr@hoya.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing